/research/taxonomy/term/566/all en /research/channels/news/diamond-therapeutics-signs-agreement-mcgill-university-research-low-dose-lsd-328282 <p>TORONTO, Feb. 4, 2021 /CNW/ - Diamond Therapeutics Inc. ("<b>Diamond</b>"), a leading psychedelic drug development company focused on low-dose therapies for mental health, has entered into an agreement with ƻ¹ûÒùԺ for the exclusive use of Dr. Gabriella Gobbi's groundbreaking studies with lysergic acid diethylamide (LSD), its mechanism of action on the brain, and its potential for use at low doses in the treatment of mental health disorders. </p> Wed, 11 Oct 2023 15:23:14 +0000 megan.liley@mcgill.ca 1257 at /research